Get the Stockscreener App
15.72
2.36%
-0.38
After Hours:
16.4899
0.7699
+4.90%
Verona Pharma Plc ADR stock is currently priced at $15.72, with a 24-hour trading volume of 717.84K.
It has seen a -2.36% decreased in the last 24 hours and a +2.75% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $16.16 pivot point. If it approaches the $15.65 support level, significant changes may occur.
Verona Pharma Plc ADR Stock (VRNA) Financials Data
Verona Pharma Plc ADR (VRNA) Net Income 2024
VRNA net income (TTM) was -$54.37 million for the quarter ending December 31, 2023, a +20.86% increase year-over-year.
Verona Pharma Plc ADR (VRNA) Cash Flow 2024
VRNA recorded a free cash flow (TTM) of -$50.22 million for the quarter ending December 31, 2023, a +16.14% increase year-over-year.
Verona Pharma Plc ADR (VRNA) Earnings per Share 2024
VRNA earnings per share (TTM) was -$0.72 for the quarter ending December 31, 2023, a +30.77% growth year-over-year.
Verona Pharma Plc ADR Stock (VRNA) Latest News
3 Healthcare Stocks That Have Outperformed Nvidia Since 2022
The Motley Fool
Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges
Zacks Investment Research
3 Stocks That Could Be Monster Winners in 2024
The Motley Fool
Verona Pharma's Promising COPD Treatment Puts It in GSK's Acquisition Crosshairs, Analysts Predict Big Moves
Benzinga
Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the Day
Zacks Investment Research
About Verona Pharma Plc ADR
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
COMPANY PROFILE
NameVerona Pharma Plc ADR
SectorHealthcare (1201)
IndustryBiotechnology (691)
Web
Phone44 20 3283 4200
Employee15
Twitter
@VeronaPharma
SEC filings
Latest SEC Filings
Next earning date2024-05-07
Address3 More London Riverside, London, United Kingdom (SE1 2RE)
1.85%
1.31%
Cap:
|
Volume (24h):